You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Anti-inflammatory and Mitotic Properties of Non-hormonal Steroids in Lung Epithel

    SBC: REVERAGEN BIOPHARMA, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Asthma is a very common lung condition in children, and incidence is increasing in the US particularly in urban and minority populations. The standard of care for asthmatics is inhaled steroid, although clinical response is variable. The mechanism of efficacy of steroids in asthma is thought to be via anti-inflammatory pathways, although other anti-inflammatory ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. COA360: Measuring Cultural Competence in Healthcare

    SBC: DayStar Research            Topic: NIMHD

    DESCRIPTION (provided by applicant): This Phase 1 STTR application seeks support for research to enhance the commercial viability of a tool to assess the cultural competence of health care organizations. The tool was developed by Dr. Thomas A. LaVeist, who is director of the Hopkins Center for Health Disparities Solutions at the Johns Hopkins Bloomberg School of Public Health. The Cultural-comp ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a BBB Model to Study Transendothelial Cell Migration

    SBC: Flocel Inc.            Topic: NIMH

    DESCRIPTION (provided by applicant): Increasing evidence indicates that systemic inflammation and the blood-brain barrier (BBB), which becomes the target of overreacting or misguided immune cells that determine BBB failure and immune extravasations into the brain parenchyma, are involved in the pathogenesis of neurological diseases such as meningitis, inflammation, Alzheimer's disease, and multipl ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Neuroprotective therapy of stroke with HUCNC and simvastatin

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): There is a compelling need to develop therapeutic approaches specifically designed to reduce neurological deficits after stroke. Human umbilical cord blood cells (HUCBCs) treatment dose-dependently improves functional outcome after stroke. UCBCs are associated with a lower risk of graft-versus-host disease (GVHD), and UCBCs are younger than adult bone marrow st ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. In vivo expansion of human hepatocytes in Fah-/-Rag-/-Il2rg-/- mice

    SBC: Yecuris Corporation            Topic: NCRR

    DESCRIPTION (provided by applicant): The liver is the site of many metabolic processes, including metabolism of xenobiotics such as pharmaceutical compounds. Drug metabolism is highly species specific and can vary significantly between individuals of the same species. To date no reliable experimental system capable of predicting the human-specific metabolic conversion of candidate small molecules ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Lentiviral-MGMT gene transfer into hematopoietic stem cells

    SBC: LENTIGEN CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): Therapeutic stem cell gene transfer relies on long-term gene expression achieved by integration of new DNA into the cellular genome. Current clinical trials featuring oncoretroviruses have encountered a number of roadblocks that include low levels of gene transfer, poor expression, and a recognized preferential insertion near promoter regions that increases the ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Intranasal Naloxone: An Opioid Overdose Antidote

    SBC: ANTIOP, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): There is a significant unmet medical need to provide additional pharmacologic treatments for treatment and prevention of opioid overdose. This Fast Track STTR project proposes to apply drug delivery technologies to develop a novel use for a nasally delivered pharmaceutical - naloxone (NLX) hydrochloride - for the emergency treatment of opioid overdose by emerge ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Recognition and Referral Skills for RAs- Alcohol-Drug Problems

    SBC: PHASE 5, INC.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Resident assistants (RAs) are often the first staff members at a college or university to learn that a student is engaged in alcohol or other drug abuse. This Phase II STTR application seeks support to further develop and test a web-based program called RA Resources (RAR) - Alcohol-Drug Problems. Phase 5, Inc. will conduct this theory-driven research project ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Commercialization of a Diagnostic Test for Alzheimer's Disease

    SBC: SCOUT DIAGNOSTICS            Topic: NIA

    DESCRIPTION (provided by applicant): The major barriers to preventing or treating Alzheimer's disease (AD) are its unknown pathogenesis/etiology and the lack of an objective, sensitive and specific biomarker of the disease, particularly at the early stages when therapeutic interventions would likely have the greatest efficacy. The basic hypothesis of this project is that levels of a unique high mo ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  10. HUCBC modulation of Alzheimer's-like pathology and behavioral changes

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): In the past years, we have shown that human umbilical cord blood cells (HUCBC, U-CORD- CELL ) provide cognitive recovery in animal models of neurodegenerative disease. Infusion of HUCBC resulted in reduced infarct volume as well as in rescue of behavioral benefits in an animal model of stroke. We further showed that HUCBC infusion proved to be beneficial in ani ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government